Pulmonary Sarcoidosis Investigational Medication

Trial Objective

Pulmonary Sarcoidosis Investigational MedicationThis research study evaluates an investigational medication called Acthar® Gel (Acthar) as a potential treatment of pulmonary sarcoidosis.


New enrollment for this trial is temporarily paused

Who Can Participate

People with biopsy-confirmed sarcoidosis for more than a year.

Age: 18-90    Gender: Any Gender

Estimated Time Commitment

Participants in the study inject the medication twice a week at home and have appointments every 4 weeks.

Study participants will need to fast prior to their visits. Visit lengths will vary.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Carmen Egidio

Carmen Egidio

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Mallinckrodt Pharmaceuticals

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.